Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease

Huilin Tang; Ying Lu; Michael S Okun; William T Donahoo; Adolfo Ramirez-Zamora; Fei Wang; Yu Huang; Wei-Han Chen; Beth A Virnig; Jiang Bian; Jingchuan Guo

doi:10.1002/mdc3.13893

Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease

Mov Disord Clin Pract. 2023 Oct 13;10(11):1659-1665. doi: 10.1002/mdc3.13893. eCollection 2023 Nov.

Authors

Huilin Tang¹, Ying Lu¹, Michael S Okun², William T Donahoo³, Adolfo Ramirez-Zamora², Fei Wang⁴, Yu Huang⁵, Wei-Han Chen¹, Beth A Virnig⁶, Jiang Bian⁵, Jingchuan Guo^{1

7}

Affiliations

¹ Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
² Department of Neurology, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, Florida, USA.
³ Division of Endocrinology, Diabetes and Metabolism, College of Medicine, University of Florida, Gainesville, Florida, USA.
⁴ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
⁵ Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.
⁶ College of Public Health and Health Professions Dean's Office, University of Florida, Gainesville, Florida, USA.
⁷ Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.

PMID: 37982117
PMCID: PMC10654811 (available on 2024-10-13)
DOI: 10.1002/mdc3.13893

Abstract

Background: The association between newer classes of glucose-lowering drugs (GLDs) and the risk of Parkinson's disease (PD) remains unclear.

Objective: The aim was to examine the effect of newer GLDs on the risk of PD through a meta-analysis of randomized outcome trials.

Methods: The methods included randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto's method.

Results: The study included 24 trials involving 33 PD cases among 185,305 participants during a median follow-up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR: 0.50; 95% CI: 0.25-0.98) than placebo.

Conclusion: Newer GLDs may possibly be associated with a decreased risk of PD; however, larger datasets are required to confirm or refute this notion.

Keywords: Parkinson's disease; glucose‐lowering drugs; meta‐analysis; randomized outcome trials; type 2 diabetes.

Abstract

Grants and funding